Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase
- 1 November 1989
- journal article
- research article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 12 (6) , 511-515
- https://doi.org/10.1016/0732-8893(89)90085-0
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion testsAntimicrobial Agents and Chemotherapy, 1988
- Beta-lactamase inhibitors from laboratory to clinicClinical Microbiology Reviews, 1988
- In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combinationJournal of Clinical Microbiology, 1987
- Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilliAntimicrobial Agents and Chemotherapy, 1986
- Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamasesAntimicrobial Agents and Chemotherapy, 1986
- Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillinAntimicrobial Agents and Chemotherapy, 1984
- Comparative Inhibition of β-Lactamases by Novel β-Lactam CompoundsAntimicrobial Agents and Chemotherapy, 1979